



Prevent health, improve management and explore alternatives for better preparedness

IVANA HALUSKOVA BALTER

Medical and scientific consultant for partnership, France

Abstract:

Bacteria, viruses, parasites and fungi that are resistant to drug cause 700,000 death each year. By 2050 superbugs inured to treatments could cause up to 10 million deaths annually and costs the global economy US\$100 trillion. (1) AMR (antimicrobial) resistance is regarded nowadays as a major threat to global public health. The issue is receiving high-level political attention (G7 and G20 in 2017 for first time). Pandemics, drug resistance and neglected diseases framing health as a “global security issue”. as recent example of coronavirus and previously Ebola .

The list was drawn up in a bid to guide and promote research and development (R&D) of new antibiotics, as part of WHO’s efforts for AMR but need to be extended.

Tuberculosis (MDR/XDR) and latent tuberculosis represent a major issue to tackle attracts global attention as witnessed by recent WHO and inter-ministerial meetings several times and figured on economic agenda given the fact of health importancy for sustainable economic growth in this interdependent and aging world

Problem of resistance get worsened due declining number of new antibiotics and limited number of new classes (2). Multifaceted strategy to promote and prioritize highly potential alternatives to tackle AMR like vaccines development is required. Vaccines like diphtheria and tetanus did not prompt resistance. In 1980 the smallpox vaccine had eradicated the naturally circulating virus worldwide without generating resistance. Recent development of LATV for pertussis shows positive off target effect where not only antibody but innate and cellular immunity plays role.

Biography:

Medical and cosmopolitan professional specialised in infectious diseases, internal medicine covering various therapeutic axes, certified in Immunology and Pediatric, MBA vaccinology and years of clinical practise contribut-



ing to bring innovative science and diplomacy for global health. Lived multi-country medical “field “experience in Southeast Asia (India in particular), West/Central/ East Europe. Speaking French, English, Russian, Italian, Czech, Slovak with notion of Mandarin. Over 15 years of experience in pharmaceutical research and development for European and USA companies (Director of R&D for new delivery platforms focused on children and elderly) for various therapeutic areas for adults and children including neurodegenerative diseases, infectious diseases and tropical diseases, metabolic diseases and orphan indications. Active member of French immunology society (SFI) administrative board and several international academic societies (focus on innovation of R&D reflecting immunology and genetic variability, role of immunologic approach for treatment and diagnostic, tackle problem of resistance for antimicrobials, antimalarial, antivirals etc). Member of advisory Health concern (India) and think tank group in order to attract attention to role of immunology, personalised and preventive medicine and accurate diagnostic and global cooperation in this area. Years of expertise to work globally within Europe, USA but recently more focused on BRICS - Asia (India in Particular) as a Medical advisor bringing new innovative concepts alive and getting them endorsed.

Publication of speakers:

1. UA/EM Tackling the antimicrobial resistance innovation crisis WHO Assembly
2. C. Loch, ” On and off” target effects of LATV, French immunology congress 2017

Webinar on Infectious Diseases | July 22, 2020 | Osaka, Japan

Citation: IVANA HALUSKOVA BALTER; Prevent health, improve management and explore alternatives for better preparedness; Infectious Diseases 2020; July 22, 2020; Osaka, Japan